Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR447537 (INBRX-101) in AATD Emphysema
NCT05897424Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 2 trial of efdoralprin alfa in alpha-1 antitrypsin deficiency (AATD), emphysema, sponsored by Sanofi. Started Jun 2024; status: active, not recruiting.
02
Drugs
efdoralprin alfa
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on NCT05897424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897424.